Barclays
BMGL

Barclays’s Basel Medical BMGL Stock Holding History

Barclays’s Portfolio BMGL Stock Details BMGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-130
Closed -$2.78K – 5785
2025
Q2 		$2.78K Buy
+130
New +$5.72K ﹤0.01% 5016

Other funds holding BMGL

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
W
WealthCollab Bellevue, Washington $243M AUM 32.93% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $3.28B AUM 23.66% 1-Year Est. Return
BIA
Bell Investment Advisors Oakland, California $639M AUM 13.28% 1-Year Est. Return

Barclays's BMGL Position: Q3 2025 in Review

Barclays sold out of Basel Medical (BMGL) in Q3 2025, closing a stake of 130 shares — an estimated $2.78K sold.

Barclays first reported a position in BMGL in Q2 2025 and held it in 1 quarter. The position peaked at $2.78K in Q2 2025. 10 funds tracked by Wall St. Rank hold BMGL as of Q3 2025.

  • Barclays reported no remaining Basel Medical position as of Q3 2025 after selling out during the quarter.
  • Barclays sold 130 Basel Medical shares in Q3 2025, an estimated $2.78K.
  • Barclays first reported a position in Basel Medical in Q2 2025 and held it in 1 quarter.
  • Barclays's Basel Medical position peaked at $2.78K in Q2 2025.
  • 10 funds tracked by Wall St. Rank held Basel Medical as of Q3 2025.

Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.